Technical Analysis for GNCA - Genocea Biosciences, Inc.
|Grade||Last Price||% Change||Price Change|
GNCA closed up 0.85 percent on Friday, January 18, 2019, on 15 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical GNCA trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||0.00%|
|Jan 18||Narrow Range Bar||Range Contraction||0.00%|
|Jan 18||NR7||Range Contraction||0.00%|
|Jan 18||Inside Day||Range Contraction||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Overbought Stochastic||Strength||0.00%|
|Jan 17||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||0.85%|
|Jan 17||Wide Bands||Range Expansion||0.85%|
|Jan 17||Overbought Stochastic||Strength||0.85%|
|Jan 16||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||-3.28%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. The company, through its proprietary discovery platform, AnTigen Lead Acquisition System (ATLAS), designs vaccines that stimulate T cell immunity. The company primarily develops GEN-003, a candidate therapeutic vaccine or immunotherapy, which is in Phase 1/2a trial to treat herpes simplex virus-2 or HSV-2 infections; and GEN-004, a T cell vaccine candidate that is in Phase 1 trial to prevent infections caused by pneumococcus. It also develops earlier-stage programs for chlamydia, HSV-2 prophylaxis, and malaria. The company, formerly known as Genocea, Inc., was founded in 2006 and is headquartered in Cambridge, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more GNCA news...
|52 Week High||1.25|
|52 Week Low||0.28|
|200-Day Moving Average||0.7238|
|50-Day Moving Average||0.5509|
|20-Day Moving Average||0.4747|
|10-Day Moving Average||0.5842|
|Average True Range||0.061|
|Chandelier Exit (Long, 3 ATRs )||0.477|
|Chandelier Exit (Short, 3 ATRs )||0.463|
|Upper Bollinger Band||0.7102|
|Lower Bollinger Band||0.2392|
|Percent B (%b)||0.74|
|MACD Signal Line||0.0032|
|Market Cap||16.89 Million|
|Num Shares||28.6 Million|
|Price-to-Earnings (P/E) Ratio||-0.29|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||0.62|
|Resistance 3 (R3)||0.62||0.62||0.62|
|Resistance 2 (R2)||0.62||0.61||0.62||0.61|
|Resistance 1 (R1)||0.60||0.60||0.60||0.60||0.61|
|Support 1 (S1)||0.58||0.59||0.58||0.58||0.57|
|Support 2 (S2)||0.58||0.58||0.58||0.57|
|Support 3 (S3)||0.56||0.58||0.57|
|Support 4 (S4)||0.56|